A Study to Evaluate the Efficacy and Safety of Ocriplasmin in Inducing Total PVD in Subjects With NPDR

NCT02681809 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

48

Enrollment

INDUSTRY

Sponsor class

Stopped Slow recruitment rate

Conditions

Diabetic Retinopathy
Posterior Vitreous Detachment
Disease Progression

Interventions

DRUG: ocriplasmin 0.0625mg
DRUG: ocriplasmin 0.125mg
DRUG: Sham injection

Sponsor

ThromboGenics